CD8A and neoplasm: BL-8040 (motixafortide) is a CXCR4 antagonist, and a phase 2 study shows that BL-8040 increases CD8+ T cell tumor infiltration, decreases myeloid-derived suppressor cells and circulating regulatory T cells (COMBAT trial) (NCT02826486) (Table 1) [44].